Preview

Siberian journal of oncology

Advanced search

Experience in performing multivisceral resections for pelvic cancer

https://doi.org/10.21294/1814-4861-2024-23-6-129-137

Abstract

Background. Treatment of patients with locally advanced pelvic cancer remains challenging. The use of modern surgical techniques has expanded the feasibilities of performing multivisceral resections (MVR) in this category of patients. However, the postoperative period in patients who have undergone MVR is associated with a high risk of developing postoperative complications. The purpose of the study was to assess the short-term and long-term treatment outcomes in patients with locally advanced and multiple-primary pelvic cancer. Material and Methods. From 2009 to 2021, 114 patients treated in the clinics of Cancer Research Institute of Tomsk National Research Medical Center underwent MVR for primary or recurrent rectal cancer (n=40, 35.1 % and n=4, 3.5 %, respectively), female reproductive cancer (endometrial cancer: n=18, 17.1 % and recurrent ovarian cancer: n=18, 17.1 %), primary and recurrent bladder cancer (n=15, 13.2 % and n=2, 1.8 %, respectively), synchronous multiple primary pelvic tumors (n=8, 7.0 %) and extraorgan mesenchymal tumors of the pelvis (n=4, 3.5 %). Paraneoplastic complications were observed in 31 (27.2 %) patients. Invasion to more than 2 adjacent pelvic organs was diagnosed in 52 (45.4 %) cases. Total pelvic evisceration (TPE) was performed in 9 (7.9 %) patients, including 5 (4.4 %) patients who underwent TPE for primary rectal cancer with extensive local spread and 4 (3.5 %) patients who underwent TPE for multiple primary cancer: 2 (1.75 %) for synchronous primary rectal cancer and bladder cancer and 2 (1.75 %) for primary rectal cancer and recurrent bladder cancer. MVR for rectal cancer was the most common (n=101, 88.6 %). Resections with the formation of colorectal anastomosis were performed in 75 (65.8 %) cases and obstructive resections of the rectum were performed in 14 (12.5 %) cases. Urinary tract surgeries were performed in 66 (57.5 %) cases. One-stage plastic surgery of the resected segment as a transposition of one or both ureters into the bottom of the bladder was performed in 22 (19.3 %) cases. Heterotopic and orthotopic plastic surgery of the bladder was performed in 19 (16.6 %) and 5 (4.4 %) cases, respectively. Combined uterine extirpations, including vaginal resection, were performed in 52 (45.4 %) cases. Grade III postoperative complications according to the Clavien–Dindo classification occurred in 18.4 % of cases. Urological complications were the most common (8.7 %). Postoperative mortality rate was 0.8 %. The assessment of the long-term outcomes was carried out using the example of patients with rectal cancer (n=45), as the most homogeneous and largest subgroup. The overall 3-year survival rate was 71.1 % and the relapse-free 3-year survival rate was 60.0 %. Conclusion. Treatment of locally advanced pelvic cancer requires extensive surgeries performed by a multidisciplinary team of surgeons. The immediate results can be assessed as satisfactory. In case of resection of the urinary tract as a component of MVR, regardless of the primary localization of the tumor, primary plastic surgery of the bladder and/or ureters is preferable. Long-term outcomes allow us to consider MVR as a method of choice in the treatment of this group of patients.

About the Authors

S. G. Afanasyev
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Sergey G. Afanasyev - MD, DSc, Professor, Head of Abdominal Oncology Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS) D-2084-2012, Author ID (Scopus) 21333316900



E. A. Usynin
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Evgeny A. Usynin - MD, DSc, Head of General Oncology Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS) D-1505-2012, Author ID (Scopus) 56204320500



I. B. Khadagaev
Novosibirsk Regional Cancer Center
Russian Federation

Igor B. Khadagaev - MD, Oncologist, Novosibirsk Regional Cancer Center.

2, Plakhotnogo St., Novosibirsk, 630108



S. A. Fursov
Novosibirsk Regional Cancer Center
Russian Federation

Sergey A. Fursov - MD, DSc, Professor, Chief Oncologist, Chief Physician, Novosibirsk Regional Cancer Center.

2, Plakhotnogo St., Novosibirsk, 630108



L. A. Kolomiets
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Larisa A. Kolomiets - MD, DSc, Professor, Head of Gynecology Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS) C-8573-2012, Author ID (Scopus) 7004921120



A. V. Usova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Anna V. Usova - MD, PhD, Senior Researcher, Diagnostic Imaging Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS) С-8968-2012, Author ID (Scopus) 57189002111



I. G. Frolova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Irina G. Frolova - MD, DSc, Professor, Head of Diagnostic Imaging Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS) C-8212-2012, Author ID (Scopus) 7006413170



О. V. Cheremisina
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation

Olga V. Cheremisina - MD, DSc, Head of Endoscopy Department, Tomsk National Research Medical Center of the Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS) C-9259-2012, Author ID (Scopus) 6602197938



References

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi: 10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020; 70(4): 313. doi: 10.3322/caac.21609.

2. Shakhzadova A.O., Starinsky V.V., Lisichnikova I.V. Cancer care to the population of Russia in 2022. Siberian Journal of Oncology. 2023; 22(5): 5–13. (in Russian). doi: 10.21294/1814-4861-2023-22-5-5-13.

3. Malignant tumors in Russia in 2023 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2024. 276 p. (in Russian).

4. Cancer. World Health Organization (in Russian). [Internet]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer. [cited 2024 Sep 1].

5. Sung X., Ferlay Ja., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71 (3): 209–49. doi: 10.3322/caac.21660.

6. Kononova G.A., Zhuikova L.D., Ananina O.A., Kolomiets L.A., Pikalova L.V., Zhuikova A.S. Reproductive system cancer in females of the Tyva Republic. Epidemiological characteristics. Siberian Journal of Oncology. 2024; 23(3): 5–14. (in Russian). doi: 10.21294/1814-4861-2024-23-3-5-14.

7. Karpenko M.O., Shostka K.G., Zagainov E.V., Shilyaev A.V., Kalinin I.V. Surgical management of locally advanced colorectal cancer. Problems in Oncology. 2024; 70(1): 105–112. (in Russian). doi: 10.37469/0507-3758-2024-70-1-105-112.

8. Doyle D.J., Hendrix J.M., Garmon E.H. American Society of Anesthesiologists Classification. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Aug 17.

9. Kaprin A.D., Suleimanov E.A., Kalinin E.V. Long-term results of extended and combined surgical interventions in patients with locally advanced rectal cancer in relation to the extent of cytoreduction. P.A. Herzen Journal of Oncology. 2017; 3: 21–28. (in Russian). doi: 10.17116/onkolog20176321-28.

10. Brown K.G.M., Solomon M.J, Koh C.E. Pelvic Exenteration Surgery: The Evolution of Radical Surgical Techniques for Advanced and Recurrent Pelvic Malignancy. Dis Colon Rectum. 2017 Jul; 60(7): 745–754. doi: 10.1097/DCR.0000000000000839.

11. Kondo A., Sasaki T., Kitaguchi D., Tsukada Y., Nishizawa Y., Ito M. Resection of the urinary bladder for locally advanced colorectal cancer: a retrospective comparison of partial versus total cystectomy. BMC Surg. 2019 Jun 17; 19(1): 63. doi: 10.1186/s12893-019-0522-8.

12. Cheremisina O.V., Menshikov K.Yu., Afanasyev S.G., Vusik M.V. Pretumor changes and synchronous gastric cancer in patients with malignant neoplasms of the lungs and ENT organs. 2015; 2: 76–78. (in Russian).

13. Afanasyev S.G., Khadagaev I.B., Fursov S.A., Usynin E.A., Gorbunov A.K., Urmonov U.B., Usova A.V., Avgustinovich A.V., Tarasova A.S. Experience of multivisceral resections for locally advanced and primary multiple rectal cancer. Avicenna Bulletin. 2020; 22(1): 82–90. (in Russian). doi: 10.25005/2074-0581-2020-22-1-82-90.

14. Bolmstrand B., Nilsson P.J., Holm T., Buchli C., Palmer G. Patterns of complications following urinary tract reconstruction after multivisceral surgery in colorectal and anal cancer. Eur J Surg Oncol. 2018; 44(10): 1513–7. doi: 10.1016/j.ejso.2018.06.017.


Review

For citations:


Afanasyev S.G., Usynin E.A., Khadagaev I.B., Fursov S.A., Kolomiets L.A., Usova A.V., Frolova I.G., Cheremisina О.V. Experience in performing multivisceral resections for pelvic cancer. Siberian journal of oncology. 2024;23(6):129-137. (In Russ.) https://doi.org/10.21294/1814-4861-2024-23-6-129-137

Views: 880


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1814-4861 (Print)
ISSN 2312-3168 (Online)